93P GD2-targeting tumor infiltrating lymphocytes for pediatric patients with central nervous system tumors

Central nervous system (CNS) tumors are among the most common pediatric cancers, but prognosis for several subtypes remains poor, particularly at relapse where curative options are lacking. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has demonstrated success in hematological malignancies, while tumor-infiltrating lymphocyte (TIL) therapy has mediated durable responses in solid tumors. Combining these approaches may generate poly-specific TILs with improved tumor recognition and clearance.